StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Tagrisso (osimertinib) — Worldwide product sales by Quarter

Tagrisso (osimertinib) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Tagrisso (osimertinib) — Worldwide product sales: $1,941M in Q2 2026, up 7.2% from a year earlier. That is the highest of the 42 quarters on record here.

Latest, Q2 2026
1,941
Period ended Jun 30, 2026
Change on a year earlier
+7.2%
1,810 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Tagrisso | 1,941 | | 7 | | 6 | | 845 | | 11 | | 512 | | 5 | | 1 | | 383 | | 9 | | 4 | | 201 | | ( 3 ) | | 2”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTagrisso (osimertinib) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,941+7.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20261,833+9.2%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20251,902+11.7%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20251,864+11.4%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20251,810+12.6%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20251,679+5.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20241,703+20.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20241,674+14.3%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20241,608+7.8%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20241,595+12.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20231,419+5.7%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20231,465+4.8%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20231,491+6.5%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20231,424+9.2%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20221,342+2.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20221,398+12.1%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up tagrisso (osimertinib) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Tagrisso (osimertinib) — Worldwide product sales ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tagrisso-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.